Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC FOLFOX + tislelizumab + lenvatinib as neoadjuvant therapy for resectable high‑risk recurrent hepatocellular carcinoma
ChiCTR2500106287Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jul 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tislelizumab, lenvatinib, oxaliplatin, folinic acid and fluorouracil in hepatocellular carcinoma (HCC), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: 1-year recurrence-free survival rate. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
tislelizumablenvatiniboxaliplatinfolinic acidfluorouracil
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500106287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106287.